Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 5.8% – Time to Sell?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) shares fell 5.8% during trading on Monday . The stock traded as low as $27.33 and last traded at $27.33. 37,775 shares were traded during mid-day trading, a decline of 90% from the average session volume of 377,997 shares. The stock had previously closed at $29.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on DMRA shares. Wedbush increased their target price on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $44.00.

Damora Therapeutics, Inc. Common Stock Price Performance

The stock’s 50-day moving average price is $29.41 and its 200 day moving average price is $26.89. The firm has a market cap of $1.74 billion, a P/E ratio of -8.35 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.06. As a group, analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System bought a new stake in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $27,429,000. Seven Fleet Capital Management LP bought a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $7,398,000. Braidwell LP bought a new position in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $42,146,000. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $6,574,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.